Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy in Relapsed or Refractory Autoimmune Diseases

Phase 1, open-label, single-arm trial of Autologous CD19-BCMA dual-target CAR T-cell therapy in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM) and 3 more, sponsored by Beijing Boren Hospital. Primary endpoint: Number and percentage of participants with adverse events (AEs), serious adverse events (SAEs), laboratory abnormalities, and adverse events of special interest (AESIs: CRS and ICANS) at 24 months. Planned start Nov 2025; status: withdrawn.